What might change is the storage requirements and concentration of your vial, but those are reconstitution and dosing considerations, not pharmacokinetic ones
On the other hand, if side effects worsen, its usually best to stick with your current dose
Home blood pressure monitoring, particularly orthostatic measurements (after 5 minutes lying down, then at 1 and 3 minutes after standing), can detect positional blood pressure changes before symptoms become problematic
No, Mounjaro is one of the brand names for tirzepatide
Tirzepatide is a once-weekly subcutaneous injectable peptide (approved by the Food and Drug Administration [FDA] for type 2 diabetes) engineered from the native GIP sequence, with agonist activity at both the GIP and GLP-1 receptors